Obesity

Obesity: Definition, Measurement, Distribution, and Global Impact

Obesity is defined by the World Health Organization as an abnormal or excessive accumulation of adipose tissue in the body such that there are adverse effects on the health and well‑being of an individual. Clinically, adiposity is commonly assessed with body mass index (BMI) or waist circumference, which reflect total body mass and central adiposity, respectively.

Measuring Obesity: BMI and Its Limitations

BMI is defined as the weight divided by the height squared, i.e. \text{BMI} = \frac{W}{H^2} where W is weight in kilograms and H is height in meters. BMI provides a rough estimate of weight-for-height but does not directly measure adiposity. The relationship between BMI and mortality has long been recognized, with a J‑shaped curve showing increased mortality risk beginning around a BMI of roughly 25–26. Higher BMI is associated with greater mortality risk, predominantly from cardiometabolic disease, but biliary disease and other causes also contribute.

There are important limitations to BMI. First, weight includes bone, muscle mass, and fluid, so BMI does not distinguish fat from lean mass. Second, BMI varies with ethnicity and age: some ethnic groups have higher or lower tolerated BMI for a given adiposity. For example, Polynesian individuals may tolerate a higher BMI before health risk rises; in older age, reduced muscle mass means a given BMI may reflect higher adiposity. There is also a sex difference: traditionally the normal BMI range for Caucasians has been 20–25, but some data suggest that men may tolerate a higher BMI (e.g., up to ~27) before risk escalates. A crucial limitation of BMI is that it does not capture fat distribution.

Abdominal Obesity: Why Waist Circumference Matters

Because BMI does not account for fat distribution, abdominal obesity provides additional and often stronger risk information. Abdominal fat accumulation—especially visceral fat around the organs—confers higher cardiometabolic risk than peripheral fat. Visceral fat is particularly pathogenic, whereas fat in the gluteal–femoral region tends to be relatively protective against cardiometabolic disease. The InterHeart study—a case‑control study of acute myocardial infarction in ~52 countries—demonstrated that abdominal obesity (measured by waist circumference/waist‑to‑hip ratio) had a stronger association with MI risk than BMI. In multivariate modelling, BMI’s association with MI risk became non‑significant once waist‑to‑hip ratio was included, underscoring the importance of fat distribution over total mass. In this context, waist circumference is a simple and practical proxy for abdominal adiposity and is measured at the narrowest point between the lower rib cage and the iliac crest (greater trochanter). Both visceral and subcutaneous fat contribute to waist circumference, but the visceral depot is most strongly linked to cardiometabolic disease.

Fat Distribution by Sex, Menopause, and Genetics

Men tend to have more visceral fat and thus higher cardiometabolic risk at a given BMI compared with women, whose fat distribution is more often peripheral (gluteal–femoral) in the premenopausal period. After menopause, women’s cardiovascular risk increases substantially as the pattern shifts toward abdominal adiposity. Fat distribution has a genetic component, with familial patterns of abnormal fat distribution evident across relatives.

Ethnic Variations in Cutoffs

Cutoffs for normal, overweight, and obesity differ by ethnicity and sex. For Caucasians, the commonly used ranges are:

  • Women: normal BMI 20–25; overweight 25–29.9; obesity ≥ 30. Some propose that men may tolerate a slightly higher BMI (up to about 27).

  • Men: normal BMI 20–25; overweight 25–29.9; obesity ≥ 30.

Waist circumference cutoffs differ by sex and ethnicity:

  • Caucasians: Women normal < 80 cm; overweight 80–88 cm; obesity > 88 cm. Men normal < 94 cm; overweight 94–102 cm; obesity > 102 cm.

  • Asians: cutoffs are lower. For Asian women, obesity is a waist circumference > 80 cm; for Asian men, obesity is a waist circumference > 85–90 cm (range reflects data limitations).

There are also height‑related considerations: some guidelines suggest comparing waist circumference to height (e.g., roughly halving height) because taller individuals can accommodate a larger waist circumference before risk increases. Extremes of height warrant individualized interpretation.

Interplay Between BMI, Waist Circumference, and Risk

Risk increases with BMI, but abdominal obesity compounds risk. For example, among individuals in the overweight BMI range (25–29.9), those with a normal or overweight waist circumference have a lower disease risk than those with an obese waist circumference. Conversely, an obese waist circumference can confer high risk even in individuals with a lower BMI, illustrating the added value of measuring waist circumference alongside BMI.

Global Prevalence and Public Health Burden

Obesity is not confined to developed nations; it is a worldwide problem. In 2016, an estimated 39% of the world’s population was overweight and 13% obese. There are large numbers of young people with obesity: approximately 41 million children under five years and about 340 million children and adolescents fall into overweight or obese categories. Obesity is now the most common non‑communicable disease globally and is largely preventable.

Obesity in Australia: Population Trends

In Australia (data from the Australian Bureau of Statistics, 2014–2015): about 63% of adults were overweight or obese (36% overweight and 28% obese). More men were overweight than women, but obesity rates were similar between sexes. Obesity and overweight are prevalent across all age groups, including young adults aged 18–24. Over time, there has been a shift in the population curve toward higher BMI categories: the prevalence of overweight remains high, but a growing proportion has progressed to obesity, indicating a rightward shift rather than a reduction in overweight prevalence.

In children and adolescents, obesity is a major concern. Among those aged 2–17 years in 2014–2015, 26% were overweight or obese overall; 18% were overweight and 8% were obese. For sex differences, boys had 20% overweight and 7% obesity; girls had 16% overweight and about 8% obesity. Rates of overweight and obesity are increasing in youth, signaling early onset of cardiometabolic risk.

Socioeconomic Status and Obesity

Obesity is more prevalent in people with lower socioeconomic status, with a particularly pronounced gradient in women. Potential contributing factors include work type, commuting time, limited time for meal planning and preparation, access to healthy foods, and the higher cost or lower subsidization of obesity treatments (pharmacotherapy, surgery) in some settings. These factors collectively influence patterns of energy balance and health behaviors.

Obesity as a Multisystem Disease

Obesity affects virtually every organ system and is associated with a wide range of diseases:

  • Brain: depression, intracranial hypertension (idiopathic intracranial hypertension, which can cause vision loss), cerebrovascular disease.

  • Cardiometabolic: diabetes mellitus type 2, dyslipidemia, hypertension, coronary heart disease, left ventricular hypertrophy, diastolic dysfunction, arrhythmias, heart failure, and vascular disease.

  • Hepatobiliary: non‑alcoholic fatty liver disease (NAFLD) spanning steatosis to cirrhosis; increasingly a leading cause of liver transplantation in some regions; hepatocellular carcinoma risk.

  • Reproductive: polycystic ovarian syndrome (PCOS) in women; hypogonadotropic hypogonadism and reduced sex hormones in men.

  • Pulmonary: sleep apnea and obesity hypoventilation syndrome, which can progress to hypoventilation and respiratory failure; increased risk of pulmonary infections.

  • Musculoskeletal: osteoarthritis (Framingham study linked knee OA in women to weight gain; 40% increased risk per 4 kg weight gain), reduced bone quality, and higher fall risk due to altered biomechanics.

  • Biliary/Gallbladder: cholelithiasis (gallstones) more common in women; often observed in clinical practice.

  • Renal: hypertension, increased risk of urinary tract infections and lower urinary tract symptoms, potential progression to renal failure.

  • Cancer: obesity increases risk for several cancers, notably endometrial, breast, colon, kidney, kidney, and gallbladder cancers; endometrial cancer shows particularly high relative risk and high population-attributable fractions for obesity.

Metabolic Syndrome and Central Obesity

Metabolic syndrome is variably defined, but a common practical definition involves the presence of high triglycerides, hypertension, or dysglycemia in association with increased waist circumference (central obesity). Central adiposity is a key driver linking dyslipidemia, dysglycemia, hypertension, and related conditions, and it is a frequent precursor to type 2 diabetes and polycystic ovarian syndrome in women.

Lipids, Vitamin D, and Other Metabolic Features

Obesity commonly accompanies a dyslipidemic profile: elevated triglycerides and low HDL cholesterol are characteristic of abdominal obesity; overall obesity may be associated with higher LDL cholesterol. Vitamin D deficiency is common in overweight/obese individuals, likely due to multifactorial causes including less sun exposure (larger skin coverage, psychosocial factors) and sequestration of vitamin D in adipose tissue.

Cardiovascular and Cerebrovascular Risks

Cardiovascular disease in obesity spans coronary artery disease, left ventricular hypertrophy, diastolic dysfunction, heart failure, arrhythmias, and hypertension. Cerebrovascular disease and dementia are also linked to metabolic abnormalities and central obesity. Intracranial hypertension is a recognized obesity‑related complication. Obesity predisposes to respiratory complications, including sleep apnea, obesity hypoventilation syndrome, and higher susceptibility to respiratory infections.

Gastrointestinal and Other Systemic Effects

Gastroesophageal reflux disease is common in obesity and can be reversible with weight loss. NAFLD can progress to cirrhosis and hepatocellular carcinoma. Cholelithiasis is more common in women and is frequently encountered in clinical practice. Obesity is also linked to several cancers; while the relative risks for some sites are modest, the population burden is substantial due to the high baseline incidence of cancers such as colon and breast cancer. In the endometrium, the cancer risk is particularly elevated in the setting of obesity, making endometrial cancer one of the strongest obesity‑related cancer associations.

Edmonton Obesity Staging System: A Practical Classification

To capture obesity‑related health burden beyond BMI, the Edmonton Obesity Staging System classifies disease as follows:

  • Stage 0: Overweight or obesity with no apparent comorbidity; normal blood pressure, normal glucose and lipids, no physical symptoms, no psychological dysfunction, and no physical limitations.

  • Stage 1: Obesity with obesity‑related risk factors (e.g., borderline hypertension, impaired fasting glucose), mild physical symptoms (e.g., occasional aches), some psychological symptoms, and mild functional limitations.

  • Stage 2: Established obesity‑related conditions (e.g., hypertension, type 2 diabetes, sleep apnea) with moderate limitations in activities of daily living.

  • Stage 3: Obesity with established organ damage (e.g., myocardial infarction, heart failure, stroke) and significant psychological disease or substantial functional impairment.

  • Stage 4: End‑stage obesity‑related disease where palliative care considerations may be appropriate due to extensive organ failure or systemic debility.

This staging concept arises from data such as NHANES (NHANES data show little difference in all‑cause mortality across BMI classes alone), but Edmonton staging demonstrates a clear gradient of mortality risk with increasing obesity‑related organ damage and comorbidity. The staging helps integrate comorbidity burden into clinical decision‑making and patient counseling.

Psychosocial Consequences and Economic Burden

Obesity has substantial psychosocial consequences. Survey data indicate that obese individuals report greater social withdrawal, reduced participation in social activities (cinema, theatre, dining, travel), lower self‑esteem, and higher rates of depression and anxiety. Obesity is associated with indirect costs such as increased sick days, higher rates of disability, and greater unemployment, with discrimination against overweight individuals affecting hiring, promotion, and wages. Presenteeism—attending work while unwell—reduces productivity and can be a major economic burden, sometimes exceeding absenteeism costs.

Depression and obesity have a bidirectional relationship. Longitudinal analyses show that overweight or obesity increases the risk of developing depression over time, and conversely, baseline depression increases the likelihood of becoming overweight or obese. This bidirectional association underscores the need for integrated approaches addressing both mood and weight management.

Practical and Public Health Implications

Obesity is a multifactorial, multisystem disease with far‑reaching health, psychosocial, and economic consequences. Measurement strategies should combine BMI with waist circumference (and, when feasible, waist‑to‑hip ratio) to more accurately stratify risk. Ethnic and sex differences in fat distribution and cutoffs must guide screening thresholds. Recognizing obesity as a chronic, progressive condition with potential organ damage reinforces the need for comprehensive, multidisciplinary management that may include lifestyle modification, pharmacotherapy, and, in selected cases, surgical interventions. Finally, addressing the social determinants of health—such as socioeconomic status and access to care—will be essential to reduce obesity prevalence and its wide‑ranging harms.